Home | Sitemap | Search | Contact A- A A+
   
 
    Public Member Support us  
 

IBCSG 12-93 

Tamoxifen for 5 years vs. toremifene for 5 years with or without chemotherapy as adjuvant therapy for post/perimenopausal, node positive, hormone receptor positive breast cancer patients.

DESIGN

Design Trial 12-93

Results & Publications


Publications

Study Chairs
Dr. Olivia Pagani - Mendrisio, Switzerland
Dr. Edda Simoncini - Brescia, Italy

Statistician
Shari Gelber

Trial Coordinator
Holly Shaw


Data Managers
Dawn Weinbaum

IBCSG Data Management Center/FSTRF
4033 Maple Road
Amherst, New York 14226 USA
Phone: +1 716 834 0900
Fax: +1 716 833 3990
Email: ibcsg10-15@fstrf.org

Date of Activation
May 1, 1993

Date of Closure
August 1, 1999

Targeted Accrual
960 patients

Final Accrual
452 patients


Results Publications Results & Publications
Other Pathology


News

24.05.2016:
The IBCSG CC will be moving. Due to the move, the office will be closed on Friday, June 3, 2016.

18.05.2016:
PINK GOLF TOUR 2016 Golf  Kyburg 25.5.2016 / Golf Gams 30.5.2016 / Golf Winterberg 7.7.2016 

05.05.2016:
New publications are available 

All News

 
  Print